Medpace Holdings, Inc. $MEDP Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,125 shares of the company’s stock after selling 53 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.07% of Medpace worth $6,316,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group raised its holdings in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after buying an additional 71 shares during the period. Whittier Trust Co. lifted its position in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after buying an additional 35 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Medpace during the first quarter worth about $60,000. Finally, Assetmark Inc. increased its position in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after acquiring an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $496.79 on Monday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55. The stock has a market cap of $13.95 billion, a P/E ratio of 36.94, a P/E/G ratio of 3.13 and a beta of 1.44. The stock has a 50-day simple moving average of $464.83 and a 200-day simple moving average of $361.31.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. During the same quarter in the previous year, the business earned $2.75 earnings per share. The firm’s revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on MEDP shares. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Mizuho increased their target price on Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Barclays increased their price target on shares of Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. Finally, Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Reduce” and a consensus price target of $422.27.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the completion of the sale, the president directly owned 36,503 shares of the company’s stock, valued at $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president owned 57,500 shares in the company, valued at approximately $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.